Measurement science expansion Koneksa positions itself as a measurement-science partner for clinical development, offering integrated physiological, clinical, and digital signals to reduce variability and clarify treatment effects. This presents an opportunity to upsell advanced data integration and analytics services to sponsors seeking earlier, decision-ready trial evidence.

New product offering The June 2026 launch of Lodestar, the first Intelligent Submission Software for clinical trials, indicates a strategic move into digital submission workflows. Sales conversations can target sponsors needing faster, more reliable regulatory submissions and explore value propositions around automation and AI-assisted data packaging.

Neuroscience collaboration Recent partnerships and trials in neuroscience, including EEG-enabled studies with Beacon Biosignals and Parkinson’s-focused research, highlight a niche where digital biomarkers and remote data capture add value. This presents a path to cross-sell digital biomarker platforms and neurodiagnostic data integration for CNS programs.

Clinical partnerships Past collaborations with Merck and the New York Proton Center demonstrate a network in pharma and advanced radiotherapy settings. Leverage these relationships to pursue new programs in oncology and precision medicine that require robust data syndication, patient-generated data, and high-fidelity endpoints.

Growth indicators With a revenue range of 25–50 million and ongoing funding of 71 million, Koneksa shows credible financial health and investor backing. This is favorable for engaging larger sponsors or early-stage programs seeking scalable measurement science and data intelligence capabilities to accelerate timelines.